David Manspeizer has more than 25 years of experience representing industry-leading, global pharmaceutical and biotechnology companies in complex patent litigation. He began his career as an intellectual property (IP) litigator at an international intellectual property law firm. There, he handled pharmaceutical and biotechnology patent litigation in US district courts, the US Court of Appeals for the Federal Circuit and the US International Trade Commission.
Prior to joining the firm, David was a partner in the IP litigation practice of two global law firms, where he led litigation teams in Hatch-Waxman and other litigation for branded pharmaceutical companies and counseled clients on due diligence, validity and infringement issues, licensing and other transactional matters, including settlements, and provided strategic patent portfolio advice. He has also served as an expert witness on licensing issues in the pharmaceutical and biotech industries.
David also served as chief intellectual property officer for Wyeth. There, he was responsible for all of the company’s patent, trademark, copyright and trade secrets matters, including all of its IP litigation matters. Additionally, he supervised diligence, counseling, strategy, IP aspects of transactions, and public policy for the corporate and pharmaceutical, consumer, and animal health divisions. While managing the department and overseeing all outside counsel activities, he supervised multiple concurrent US and foreign patent and trademark litigations, including Hatch-Waxman and other litigation concerning the company’s blockbuster Effexor® XR, Protonix® and Enbrel® products. He also led the effort that resulted in the decision in Wyeth v. Kappos, which effected a major change in the way that patent term adjustment is calculated. Furthermore, he managed royalty buyouts for a multibillion-dollar biologic product, designed the litigation and settlement strategy for a third-party suit alleging patent infringement by a multibillion-dollar product, and directed a strategic patent portfolio focus that yielded a top ranking on The Wall Street Journal’s patent scorecard for eight consecutive quarters (2007–2009).
David was named an IP Star by Euromoney Legal Media Group’s Managing IP 2014-2016 and 2018-2019 and a "Patent Star" by LMG Life Sciences in 2018. He is also recommended by The Legal 500 US 2017 in the practice area of Patent Litigation.